ViralClear Pharmaceuticals partners with Albany Molecular Research Inc. on the manufacture of merimepodib active pharmaceutical ingredient development for the potential treatment of COVID-19 July 8, 2020
BioSig Technologies, Inc. Announces $17.5 Million Common Stock Only Registered Direct Offering June 24, 2020
ViralClear Opens Enrollment with First Patient Dosing in Phase II Human Trial of Anti-Viral MMPD Oral Solution for Treatment of COVID-19 June 17, 2020
Reminder - BioSig Subsidiary, ViralClear to Host Conference Call on June 9th to Discuss Upcoming and Recent Developments for Phase II Human Clinical Trials of its Broad-Spectrum Oral Anti-Viral Candidate for Treatment of COVID-19 June 8, 2020
ViralClear adds St. David's HealthCare in Austin, Texas, to its Planned Phase II trial for its Broad-Spectrum Oral Anti-Viral Candidate for COVID-19 June 5, 2020
BioSig Technologies’s PURE EP System to be Presented in Heart Rhythm Society 2020 Science Sessions June 4, 2020
